Trastuzumab Recruiting Phase 2 Trials for Tubular Breast Cancer Stage II / Invasive Ductal Breast Carcinoma / Tubular Breast Cancer Stage III / Mucinous Breast Cancer Stage II / HER2 Positive Breast Cancers / Malignant Neoplasm of Female Breast / Inflammatory carcinoma of the breast Treatment

Indications	Status	Purpose	Phase
DBCOND0053760 (Tubular Breast Cancer Stage II) DBCOND0047004 (Invasive Ductal Breast Carcinoma) DBCOND0053764 (Tubular Breast Cancer Stage III) DBCOND0053761 (Mucinous Breast Cancer Stage II) DBCOND0066412 (HER2 Positive Breast Cancers) DBCOND0064161 (Malignant Neoplasm of Female Breast) DBCOND0017409 (Inflammatory carcinoma of the breast)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02682693	Denosumab as an add-on Neoadjuvant Treatment (GeparX)	Pertuzumab (DB06366) Denosumab (DB06643) Cyclophosphamide (DB00531) Paclitaxel (DB01229) Epirubicin (DB00445) Trastuzumab (DB00072) Carboplatin (DB00958)
NCT02614794	Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer	Trastuzumab (DB00072) Capecitabine (DB01101) Tucatinib (DB11652)